Literature DB >> 661706

Cardiological effects of nomifensine, a new antidepressant.

G D Burrows, J Vohra, P Dumovic, B A Scoggins, B Davies.   

Abstract

A cardiovascular study of a new antidepressant, nomifensine, revealed no significant cardiac effects in eight ambulant patients who received up to 200 mg of nomifensine per day for three weeks. In an electro-physiological study of cardiac conduction, nomifensine had significantly less effect on cardiac activity than amitriptyline and doxepin. Results of the clinical and the experimental studies suggest that nomifensine may be of value in treating the depressed patient with heart disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 661706     DOI: 10.5694/j.1326-5377.1978.tb107898.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  Interaction of alcohol with maprotiline or nomifensine: echocardiographic and psychometric effects.

Authors:  C Strömberg; A Suokas; T Seppälä
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  A double-blind trial of mianserin and nomifensine in depressed outpatients.

Authors:  W Hamouz; R Van Dorth; R M Pinder; S M Stulemeijer
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

3.  Nomifensine: A review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.